OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

BIOGEN INC. DL -,0005/  US09062X1037  /

Hannover
2024-04-30  8:45:06 AM Chg. +6.40 Volume Bid10:00:02 PM Ask10:00:02 PM Market Capitalization Dividend Y. P/E Ratio
200.70EUR +3.29% 0
Turnover: 0.00		 -Bid Size: - -Ask Size: - 29.37 bill.EUR - -
GlobeNewswire 04-25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 04-24 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 04-02 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 03-06 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 03-04 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 02-23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 02-13 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 02-12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
TeleTrader 02-12 Earnings preview: Robinhood, Coinbase and more
GlobeNewswire 02-08 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire 01-04 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer
GlobeNewswire 2023-12-19 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire 2023-12-15 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire 2023-12-14 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...
TeleTrader 2023-11-08 Biogen's Q3 revenue up 3% to $2.5B
GlobeNewswire 2023-11-06 Biogen Appoints Monish Patolawala to its Board of Directors
GlobeNewswire 2023-10-25 Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire 2023-10-25 New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise f...
GlobeNewswire 2023-10-19 Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GlobeNewswire 2023-09-29 FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
GlobeNewswire 2023-09-26 Biogen Completes Acquisition of Reata Pharmaceuticals
TeleTrader 2023-09-25 Japan approves Eisai-Biogen Alzheimer's drug
GlobeNewswire 2023-09-25 LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
GlobeNewswire 2023-09-06 Biogen Appoints Jane Grogan as Head of Research